The R&D centre will endeavour to bring scientifically advanced biological, biotechnology products and novel drug delivery systems
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
The brand is now available pan-India through their distribution partner
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Biogen paid Ionis a US $ 60 million one-time upfront payment
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
Subscribe To Our Newsletter & Stay Updated
